Stem Cell Therapeutics to Provide Update on CD47 Program at the 2014 American Association for Cancer Research Annual Meeting
April 03 2014 - 7:00AM
Marketwired
Stem Cell Therapeutics to Provide Update on CD47 Program at the
2014 American Association for Cancer Research Annual Meeting
Announcing a key difference between SIRPaFc and other
CD47-blocking agents
TORONTO, ONTARIO--(Marketwired - Apr 3, 2014) - Stem Cell
Therapeutics Corp. (TSX-VENTURE:SSS)(OTCQX:SCTPF), an
immuno-oncology company developing cancer stem cell-related
therapeutics, today announced it will be providing an update on its
SIRPaFc immune checkpoint inhibitor program, targeting the CD47
protein, at the 105th Annual Meeting of the American Association
for Cancer Research. The meeting will be held April 5-9, 2014 in
San Diego, CA. Details of the poster presentation, entitled
"Cancer Immunotherapy Targeting CD47: Wild Type SIRPaFc is the
Ideal CD47-Blocking Agent to Minimize Unwanted Erythrocyte
Binding", are listed below:
Date: Wednesday April 9, 2014 |
Time: 8:00 am - 12:00 pm (PT) |
Session ID: Immunology 11 |
Session Title: Immune Checkpoint Inhibition
Abstract #: 5011 |
Presenter: Dr. Robert Uger, Chief
Scientific Officer |
Location: Hall A-E, Poster Section 10, San
Diego Convention Center |
The company will
present data demonstrating that its wild type SIRPaFc fusion
protein, which binds effectively to CD47 with low nanomolar
affinity, binds very poorly to human red blood cells (RBCs)
compared to both commercial anti-CD47 monoclonal antibodies (mAbs)
and proprietary CD47-blocking agents. This striking difference in
binding was not seen with other cell types, including acute myeloid
leukemia (AML) tumor cells, suggesting it is an RBC-specific
phenomenon. In addition, the lack of significant SIRPaFc binding to
erythrocytes is unique to humans, since SIRPaFc bound strongly to
mouse and non-human primate RBCs. Overall, the data suggest that a
wild type SIRPaFc fusion protein may be the ideal CD47-blocking
agent to reduce the potential antigen sink effect caused by RBCs
and to minimize hematological toxicity in patients, while
maintaining potent anti-tumor effects.
"Our results are
consistent with independently publ ished reports documenting
differences in binding between CD47-specific antibodies and the
natural CD47 ligand, SIRPa. While the mechanism behind this
observation is still under investigation, our preliminary data
suggest that it may relate to unique structural features of CD47 in
the human RBC membrane," commented Dr. Uger. "Importantly, our re
sults indicate that our SIRPaFc protein has a preferable RBC
binding profile compared to competing approaches, which we believe
may predict a lower risk of toxicity in patients and a more
favorable pharmacokinetic profile."
About Stem Cell
Therapeutics:
Stem Cell
Therapeutics Corp. (SCT) is an immuno-oncology company advancing
cancer stem cell discoveries into novel and innovative cancer
therapies. The Company has two premier preclinical programs, a
SIRPaFc fusion protein and a CD200-specific monoclonal antibody
(mAb), which target two key immunoregulatory pathways that tumor
cells exploit to evade the host immune system. SIRPaFc is an
antibody-like fusion protein that blocks the activity of CD47, a
molecule that is upregulated on cancer stem cells and bulk tumor
cells in acute myeloid leukemia (AML), and several other tumors.
The CD200 mAb is a fully human mAb that blocks the activity of
CD200, an immunosuppressive molecule that is overexpressed by many
hematopoietic and solid tumors. SCT's clinical stage programs
include tigec ycline, which is currently being evaluated in a
multi-centre Phase I study in patients with AML, and TTI-1612, a
non-cancer stem cell asset that has completed a 28-patient Phase I
trial in interstitial cystitis patients. For more information,
visit: www.stemcellthera.com.
Caution Regarding
Forward-Looking Information:
This press release
may contain forward-looking statements, which reflect SCT's current
expectation regarding future events. These forward-looking
statements involve risks and uncertainties that may cause actual
results, events or developments to be materially different from any
future results, events or developments expressed or implied by such
forward-looking statements. Such factors include changing market
conditions; the successful and timely completion of pre-clinical
and clinical studies; the establishment of corporate alliances; the
impact of competitive products and pricing; new product development
risks; uncertainties related to the regulatory approval process or
the ability to obtain drug product in sufficient quantity or at
standards acceptable to health regulatory authorities to complete
clinical trials or to meet commercial demand; and other risks
detailed from time to time in SCT's ongoing quarterly and annual
reporting. Except as required by applicable securities laws, SCT
undertakes no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.
Neither TSX Venture
Exchange nor its Regulation Services Provider (as that term is
defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.
Stem Cell Therapeutics Corp.James ParsonsChief Financial
Officer+1 416 595
0627jparsons@stemcellthera.comwww.stemcellthera.comInvestor
Contact:ProActive CapitalJeff Ramson/Kirin Smith+1
646-863-6519jramson@proactivecapital.comksmith@proactivecapital.com
Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Apr 2023 to Apr 2024